EP0506880A1 - Organo-metallic coated particles for use in separations - Google Patents

Organo-metallic coated particles for use in separations

Info

Publication number
EP0506880A1
EP0506880A1 EP19910902915 EP91902915A EP0506880A1 EP 0506880 A1 EP0506880 A1 EP 0506880A1 EP 19910902915 EP19910902915 EP 19910902915 EP 91902915 A EP91902915 A EP 91902915A EP 0506880 A1 EP0506880 A1 EP 0506880A1
Authority
EP
European Patent Office
Prior art keywords
particle
organo
titanium
iron
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19910902915
Other languages
German (de)
French (fr)
Inventor
Mark S. Chagnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular BioQuest Inc
Original Assignee
Omni Quest Corp
Molecular BioQuest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omni Quest Corp, Molecular BioQuest Inc filed Critical Omni Quest Corp
Publication of EP0506880A1 publication Critical patent/EP0506880A1/en
Ceased legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B03SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03CMAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00Magnetic separation
    • B03C1/005Pretreatment specially adapted for magnetic separation
    • B03C1/01Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • G01N33/5434Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/20Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/80Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/80Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/84Polymer coating, e.g. gelatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/80Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/90Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids characterised by small molecule linker used to couple immunoreagents to magnetic particles

Definitions

  • magnetic particles When used as solid supports in immunoassays or other competitive binding assays, magnetic particles permit the reaction to occur under homogeneous conditions, which promotes optimal binding kinetics, minimally alters analyte-adsorbent equilibrium and facilitates separation of bound from unbound analyte, particularly as compared to centrifugation.
  • Centrifugal separations are time-consuming, require expensive and energy-consuming equipment and pose radiological, biological and physical hazards. Magnetic separations are relatively rapid and easy, requiring simple equipment.
  • the use of non-porous adsorbent- coupled magnetic particles in affinity chromatography systems allows better mass transfer and results in less fouling of the sample than in conventional affinity chromatography systems.
  • Small magnetic particles e.g., having a mean diameter in solution less than about 0.03 microns
  • the magnetic field and magnetic field gradient required to remove such particles from solution are large and require heavy and bulky magnets for generating these fields, which are inconvenient to use in bench top work.
  • Magnets capable of generating magnetic fields in excess of 5000 Oersteds, for example, are typically required to separate magnetic particles of less than 0.03 microns in diameter.
  • the ferromagnetic carrier particles must generally be coated in order to provide a reactive substrate for attaching chemical functional groups to bind enzymes or antibodies, for example.
  • Silane polymers are often used for this purpose.
  • Particles described in U.S. Patent No. 3,933,997 are coated with silanes capable of reacting with anti-digoxin antibodies to chemically couple the antibodies to the carrier particles.
  • Various silane couplings are discussed in U.S. Patent No. 3,652,761, which is hereby incorporated by reference. Procedures for silanization known in the art generally differ from each other in the media chosen for the polymerization of silane and its disposition on reactive surfaces.
  • the medium is generally an organic solvent such as toluene (H.W., Weetall, In: Methods of Enzymology, K. Mosbach (ed), 44:134-148, 140 (1976)), methanol (U.S. Patent No. 3,933,997) or chloroform (U.S. Patent No. 3,652,761). Silane depositions from aqueous alcohol and aqueous solutions with acid have also been used. H.W. Weetall, In: Methods in Enzymology, supra, p.139 (1976).
  • silane-coated particles There are several drawbacks to silane-coated particles.
  • the dehydration methods used to dry the coatings such as air and/or oven drying, allow the silanized surfaces of the carrier particles to contact each other, potentially resulting in interparticle bonding, including cross-linking between particles by siloxane formation, van der Waals interactions or physical adhesion between adjacent particles.
  • This interparticle bonding yields covalently or physically bonded aggregates of silanized carrier particles of considerably larger diameter than individual carrier particles.
  • Such aggregates have low surface area per unit weight and hence, a low capacity for coupling with molecules such as antibodies, antigens or enzymes. Such aggregates also have gravitational settling times which are too short for many applications.
  • Radioimmunoassay is a term used to describe methods for analyzing the concentrations of substances involving a radioactively labeled substance which binds to an antibody. The amount of radioactivity bound is altered by the presence of an unlabeled test substance capable of binding to the same antibody. The unlabeled substance, if present, competes for binding sites with the labeled substance and thus decreases the amount of radioactivity bound to the antibody. The decrease in bound radioactivity can be correlated to the concentration of the unlabeled test substance by means of a standard curve.
  • An essential step of RIA is the separation of bound and free label which must be accomplished in order to quantitative the bound fraction.
  • Coated tubes such as described in U.S. Patent No, 3.646,346 allow separation of bound and free label without centrifugation but suffer from two major disadvantages.
  • Antibodies have been attached to particulate systems to facilitate separations.
  • U.S. Patent Nos. 3,652,761 and 3,555,143 Such systems have large surface areas permitting nearly unlimited amounts of antibody to be used, but the particulates frequently settle during the assay. The tube frequently must be agitated to achieve even partial homogeneity P.M. Jacobs, The Ligand Quarterly, 4(4): 23-33 (1981). Centrifugation is still required to effect complete separation of bound and free label.
  • Antibodies may react with labeled and unlabeled molecules followed by separation using a second antibody raised to the first antibody.
  • the technique termed the doubled antibody method, achieves homogeneity of antibody during reaction with label but requires an incubation period for reaction of first and second antibodies followed by a centrifugation to pellet the antibodies.
  • Antibodies have been attached to magnetic supports in an effort to eliminate the centrifugation steps in radioimmunoassays for nortriptyline, methotrexate, digoxin, thyroxine and human placental lactogen.
  • Antiestradiol antibodies were coupled to such particles and their potential usefulness in estradiol RIAs was demonstrated. While this approach may have over come the problem of settling, the particle size and the magnetic coating nonetheless present limitations on surface area and hence limitations on the availability of sites for antibody coupling.
  • Magnetic separations have been applied in other biological systems besides RIA.
  • Several nonisotopic immunoassays such as fluoroimmunoassays (FIA) and enzyme-immunoassays (EIA) have been developed which employ antibody-coupled (or antigen coupled) magne t i c particles.
  • FIA fluoroimmunoassays
  • EIA enzyme-immunoassays
  • the principle of competitive binding is the same in FIA and EIA as in RIA except that fluorophores and enzymes, respectively, are submitted for radioiso- topes as label.
  • Kamel et al. developed magnetizable solid-phase FIA's for cortisol and phenyltoin, respectively, utilizing ferromagnetic cellulose/iron oxide particles to which antibodies were coupled by cyanogen bromide activation.
  • a magnetizable solid phase non-immune radioassay for vitamin B12 has been reported by D.S. Ithakissios and D.O. Kubiatowicz Clin. Chem., 23(11) : 2072 - 2079 (1977).
  • the principle of competitive binding in non-immune radioassays is the same as in RIA with both assays employing radioiso topic labels.
  • RIA is based on the binding or interaction of certain biomolecules like vitamin B12 with specific or non-specific binding, carrier, or receptor proteins.
  • the magnetic particles of Ithakissios and Kubiatowicz were composed of barium ferrite particles embedded in a water-insoluble protein matrix.
  • magnetic particles have been used for a variety of other biological purposes.
  • magnetic particles have been used in cell sorting systems to isolate select viruses, bacteria and other cells from mixed populations.
  • Magnetic particles have also been used as the solid phase support immobilized enzyme systems.
  • Enzymes coupled to magnetic particles are contacted with substrates for a time sufficient to catalyze the biochemical reaction. Thereafter, the enzyme can be magne- tically separated from products and unreacted substrate and potentially can be reused.
  • Magnetic particles have been used as supports for ⁇ -chymotrypsin, ⁇ -galactos idase (U.S. Patent No. 4,152,210), hereby incorporated by reference) and glucose isomerase (U.S. Patent No. 4,343,901, hereby incorporated by reference) in immobilized enzyme systems.
  • the present invention relates to magnetically responsive particles coated with an organo-metallic polymer capable of binding bioaffinity adsorbents, and to their use in the separation of biological molecules from, or directed movement of the molecules in, the surrounding medium.
  • the organo-metallic coating is adsorbed onto or covalently bound to the magnetic particle.
  • the magnetic particles comprise a magnetically responsive metal, metal alloy, or metal oxide core surrounded by an organo-metallic polymer coating which is adsorbed or covalently bound to the particle.
  • the organo-metallic polymer is formed from an organo-metallic monomer, which is applied to the metal particle, and thermally cross-linked in situ to form an adsorbed or a covalently bound polymer coating.
  • Organo-titanium polymers are preferred, however, organo-metallic polymers formed from coordinate complexes of other transition metals, such as zirconium (Zr), hafnium (Hf), vanadium (V), tantalum (Ta) and niobium (Nb), or post-transition metals, such as tin (Sn) and antimony (Sb), can be used.
  • Zr zirconium
  • Hf hafnium
  • V vanadium
  • Ta tantalum
  • Nb niobium
  • post-transition metals such as tin (Sn) and antimony (Sb)
  • a wide variety of bioaffinity adsorbents can be covalently bonded to the organo-metallic polymer coating through selected coupling chemistries.
  • the invention relates to methods for the preparation of magnetically responsive particles comprising a metal, metal alloy or metal oxide core and an organo-metallic coating having an aliphatic moiety and an organic functionality to which a variety of organic and/or biological molecules can be coupled.
  • the particles, coupled or uncoupled, can be dispersed in aqueous media forming a colloidal dispersion which is stable, that is, the particles resist rapid gravitational settling.
  • the particles can be reclaimed from the media by applying a magnetic field.
  • the particles are superparamagnetic; that is, they exhibit no reminent magnetization after removal of a magnetic field which allows the particles to be redispersed without magnetic aggregate formation.
  • the organo-metallic coated magnetically responsive particles of the invention may be coupled through the organic functionality to biological or organic molecules with affinity for, or the ability to adsorb, or which interact with, certain other biological or organic molecules. Particles so coupled may be used in a variety of in vitro or in vivo systems involving s ep arat i ons steps or the directed movement of coupled molecules to particular sites, including immunological assays, other biological assays, biochemical or enzymatic reactions, affinity chromatographic purification, cell sorting and diagnostic and therapeutic uses.
  • the present organo-metallic coated magnetic particles provide superior composition, size, surface area, coupling versatility, settling properties and magnetic behavior for use in biological separations.
  • the magnetic particles of this invention are suitable for many of the assays, enzyme immobilization, cell sorting and affinity chromatography procedures reported in the literature and, in fact, overcome many of the problems associated with particle settling and reuse experienced in the past with such procedures.
  • the magnetically responsive particles of this invention overcome problems associated with the size, surface area, gravitational settling rate and magnetic character of previously developed magnetic particles. Gravitational settling times in excess of about 24 hours can be achieved with the present magnetic particles.
  • the gravitational settling time is defined to be the time for the turbidity of a dispersion of particles to fall by fifty percent in the absence of a magnetic field gradient.
  • the present magnetic particles comprise a core of a magnetically responsive metal, metal alloy or metal oxide, coated with organo-metallic polymer, which is capable of binding reactive groups or agents, for example, chemically reactive groups, biologically reactive groups or bioaffinity agents.
  • the organo- metallic polymer is adsorbed onto or covalently bound to the magnetic particle.
  • the term "magnetically responsive particle” or “magnetic particle” is defined as any particle dispersible or suspendible in aqueous media without significant gravitational settling, and separable from suspension by application of a magnetic field.
  • magnetic core is defined as a crystal or group (or cluster) of crystals of a transition metal, alloy or magnetic metal oxide having ferrospinel structure and comprising trivalent and divalent cations of the same or different transition metals or magnetic metal crystal group.
  • Metals, alloys and oxides which are useful as magnetic core material in the present invention include the metals, alloys and oxides based on metals which appear in the Periodic Table in Groups 4a and b, 5a and b, 6a and 7a.
  • divalent transition metals such as iron, magnesium, manganese, cobalt, nickel, zinc and copper
  • alloys of these metals such as iron alloys or oxides (e.g., iron magnesium oxide, iron manganese oxide, iron cobalt oxide, iron nickel oxide, iron zinc oxide and iron copper oxide), cobalt ferrite, samarium cobalt, barium ferrite, and aluminum - ni ckel - c ob al t and metal oxi de s inc luding magnetite (Fe 3 O 4 ), hematite (Fe 2 O 3 ) and chromium dioxide (CrO 2 ).
  • divalent transition metals such as iron, magnesium, manganese, cobalt, nickel, zinc and copper
  • alloys of these metals such as iron alloys or oxides (e.g., iron magnesium oxide, iron manganese oxide, iron cobalt oxide, iron nickel oxide, iron zinc oxide and iron copper oxide), cobalt ferrite, samarium
  • a magnetic core may be comprised of a cluster of superparamagnetic crystals of iron oxide, or a cluster of superparamagnetic or ferromagnetic crystals of irons or oxide, or may consist of an single superparamagnetic or ferromagnetic crystal of an iron oxide or metal alloy.
  • the present particles are preferably between about 0.003 and about 1.5 microns in diameter, and have a surface area of from about 50 to 150 meters/gm, which provides a high capacity for coupling of a bioaffinity adsorbent, chemical or biochemical reactive group.
  • Magnetic particles of this size range overcome the rapid settling problems of larger particles, but obviate the need for large magnets to generate the magnetic fields and magnetic field gradients required to separate smaller particles.
  • magnets used to effect separations of the magnetic particles of this invention need only generate magnetic fields between about 100 and about 1000 Oersteds. Such fields can be obtained with permanent magnets which are smaller than the container which holds the dispersion of magnetic particles and, thus, are suitable for benchtop use.
  • superparamagnetic particles do not exhibit the magnetic aggregation associated with ferromagnetic particles and permit redispersion and reuse.
  • superparamagnetism is defined as that magnetic behavior exhibited by iron, cobalt, nickel or other metal alloys or metal oxides having a crystal size of less than about 300A, which behavior is characterized by responsiveness to a magnetic field without reminant magnetization.
  • Ferromagnetic particles may be useful in certain applications of the Invention.
  • the term "ferromagnetism” is defined as that magnetic behavior exhibited by Iron, iron alloys or iron oxides with a crystal size greater than about 500A, which behavior is characterized by responsiveness to a magnetic field with a reminant magnetization of greater than about 10 gauss upon removal of the magnetic field.
  • Organo-metallic monomers useful for the present coated particles are organic coordinate complexes of selected transition and/or post transition metals which are capable of forming a stable coordination coumpound, and organic ligands, which can be adsorbed onto or covalently bound to the magnetic particle and, crosslinked in situ on the particle surface, thereby forming the organo-metallic polymer coating.
  • the organo-metallic monomer must be able to be functionalized or derivatized in a manner that allows the polymer formed therefrom to form covalent bonds with bioaffinity or chemical affinity adsorbents.
  • the organo-metallic polymer is post- functionalized or derlvitized with an aliphatic "spacer arm" which is terminated with an organic functional group capable of coupling with bioaffinity adsorbents.
  • the "spacer arm” is an aliphatic hydrocarbon having from about 2 to about 60 atoms, e.g., carbon, nitrogen and/or oxygen atoms.
  • the purpose of the spacer arm is to provide a non-reactive linker (or spacer) between the organic group which reacts with the chemical group, biochemical group or bioaffinity adsorbent and the polymer chain, and to impart an appropriate degree of hydrophilic/hydrophobic balance to the surface of the coated particle.
  • organo-metallic compounds are coordinate complexes formed from selected transition metals (e.g., Ti, Zr, Hf, V, Zn, Cd, Mn, Te, Re, Ta, Nb) and/or post-transition metals (e.g., Sn, Sb, Al, Ga, In, Ge).
  • transition metals e.g., Ti, Zr, Hf, V, Zn, Cd, Mn, Te, Re, Ta, Nb
  • post-transition metals e.g., Sn, Sb, Al, Ga, In, Ge.
  • Organo-titanium compounds are parti cul ar ly preferred.
  • Organo-titanium compounds which are us e ful including, for example, titanium - tetra - isopropoxide, amino - hexyl - titanium - tri - isopropoxide, amino-propyl- titanium - tri - isopropoxide and carboxyl -hexyl - titanium- tri - isopropoxide.
  • amino -hexyl - titanium- tri - isoproxide is coated onto the magnetic particle of choice, and thermally crosslinked to form an organo-titanium polymer coating having an aliphatic spacer arm (the hexyl moiety) and organic functional group (the amine group).
  • the coated particle is post-functionalized, if necessary, in a manner that allows the organo-metallic polymer to form covalent bonds with bioaffinity or chemical affinity adsorbents.
  • an organo-titanium polymer such as titanium- tetra- isopropoxide which lacks the spacer arm and organic functional group, is coated onto the magnetic particle of choice and partly crosslinked at about 40°C for a period of time sufficient to allow the organotitanium polymer to become adsorbed onto the particle surface.
  • the organotitanium coated magnetic particle is then activated by reaction with an agent such as 1-hydroxy- 6-amino hexane, to form the amino-hexyl- titanium- tri- isopropoxide.
  • the coating is then crosslinked at elevated temperatures to form an organotitanium polymer coating having an aliphatic spacer arm and an organic functionality (i.e., the amine group).
  • the functionalized particle can then be reacted or coupled, with the bioaffinity adsorbent of choice.
  • the magnetic core particles are prepared according to the following general procedure: metal salts are precipitated in a base to form fine magnetic metal oxide crystals. The crystals are redlspersed, then washed in water and in an electrolyte. Magnetic separation can be used to collect the crystals between washes if the crystals are superparamagnetic.
  • superparamagnetic iron oxide particles are made by precipitation of divalent (Fe 2+ ) and trivalent (Fe 3+ ) iron salts, for example, ferrous ammonium sulfate, Fe 2 (NH 2 )(SO 4 ) and ferric sulfate, Fe 2 (SO 4 ) 3 , in aqueous base.
  • the ratio of Fe 2+ and Fe 3+ and counterion can be varied wi thout substantial changes in the final product by increasing the amount of Fe 2+ while maintaining a constant molar amount of iron.
  • Counterions including nitrate, sulfate, chloride or hydroxide are useful in the method.
  • a Fe 2+ /Fe 3+ ratio of about 2:1 to about 4:1 is useful in the present invention; a ratio of about 2:1 Fe 2+ : Fe 3+ is particularly useful.
  • An Fe 2+ /Fe 3+ ratio of 1:1 produces magnetic particles of slightly inferior quality to those resulting from the higher Fe 2+ /Fe 3+ ratios, the particle size is more heterogeneous than that resulting from Fe 3+ /Fe 2+ of 2:1 or 4:1.
  • aqueous solutions of the iron salts are mixed in a base, such as ammonium, sodium or potassium hydroxide, which results in the formation of a crystalline precipitate of superparamagnetic iron oxide.
  • a base such as ammonium, sodium or potassium hydroxide
  • the precipitate is washed repeatedly with water by magnetically separating and redispersing it until a neutral pH is reached.
  • the precipitate is then washed with about five equal portions of a water miscible solvent, such as acetone, methanol or ethanol that has been dried over molecular sieves to remove all of the water.
  • divalent transition metal salts such as magnesium, manganese, cobalt, nickel, zinc and copper salts may be substituted for iron salts in the precipltation or milling procedure to yield magnetic metals or metal oxides.
  • divalent cobalt chloride (CoCl 2 ) for FeCl 2 in the above procedure produced ferromagnetic metal oxide particles. Ferromagnetic metal oxide particles such as those produced with CoCl 2 can be washed in the absence of magnetic fields by employing conventional techniques of centrifugation or filtration between washings to avoid magnetizing the particles.
  • the resulting ferromagnetic metal oxides are of sufficiently small diameter to remain dispersed in aqueous media, they can also be coated with the organo-metallic polymer and coupled to bioaffinity adsorbents for use in systems requiring a single magnetic separation, e.g., certain radioimmunoassays. Ferromagnetism limits particle usefulness in those applications requiring redispersion or reuse.
  • the magnetic core particles can be made by precipitating metal powders and reducing the particle size by milling the resulting precipitate, for example, in a ball mill.
  • the metal powder is precipitated from an aqueous solution of, for example, Fe +2 or Fe +3 salt with sodium borohydride.
  • an aqueous solution of ferrous chloride (FeCl 2 ) is mixed with sodium borohydride
  • the magnetic metal powder is then collected by filtration and washed with about five equal volumes of water to remove all soluble salts, then washed with five equal volumes of dry in acetone to remove all residual water.
  • the particle is added as an aqueous slurry in a concentration of about 1-25% to a c omme rc i al ball mill filled half way with 1/4" stainless steel balls and milled for 3-30 days.
  • a superparamagnetic metal slurry is formed and coated and functionalized as the superparamagnetic particles described in the previous section.
  • the magnetic core particles are made by reacting a metallocene, e.g., particulate ferrocene (dicyclopentadenyliron, C 10 H 10 Fe) with iron (II) hydroxide.
  • a metallocene e.g., particulate ferrocene (dicyclopentadenyliron, C 10 H 10 Fe)
  • iron (II) hydroxide iron (II) hydroxide.
  • an aqueous ferrocene (or other metallocene) slurry is prepared, and an aqueous slurry of Iron (II) hydroxide is prepared separately.
  • the ferrocene slurry is prepared, for example, by milling a mixture of ferrocene and water in a ball mill.
  • the iron (II) hydroxide slurry can be prepared, for example, by precipitating an aqueous solution of ferrous sulfate with ammonium hydroxide to form ferrous hydroxide. The two slurries are then combined and milled, for example, forming fine magnetite particles. Other metallocene compounds (e.g., nickelocene, cobaltocene) can be mixed with the ferrocene to produce various magnetic ferrite particles. This process is described in detail in co-pending U.S. patent application Serial No. _________,
  • the coating around the magnetic core particle is amino-pro- pyl- titanium- tri- isopropoxide.
  • the polymerization is performed by redispersing the magnetic particle in an acetone solution, adding the organo-titanium monomer, then crosslinking with heat.
  • Coupled magnetically responsive particle or “coupled magnetic particle” refer to any magnetic particle to which one or more types of bioaffinity adsorbents are coupled by covalent bonds, which covalent bonds may be amide, ester, ether sulfonamide, disulfide, azo or other suitable organic linkages depending on the functionalities available for bonding on both the coating of the magnetic particle and the bioaffinity adsorbents.
  • Preferred magnetically responsive particles of the present Invention have metal oxide cores composed of clusters of superparamagnetic crystals affording efficient separation of the particles in low magnetic fields (100-1000 Oersteads) while maintaining super- paramagnetic properties.
  • Aggregation of particles is controlled during particle synthesis to produce particles which are preferably small enough to avoid substantial gravitational settling over times sufficient to permit dispersions of the particles to be used in an intended biological assay or other application.
  • the advantage of having superparamagnetic cores in magnetically responsive particles is that such particles can be repeatedly exposed to magnetic fields. Superparamagnetic particles do not exhibit reminent magnetization and have no coercive strength, and, therefore, do not ma gne ti c al ly aggregate, thus, the particles can be redispersed and reused.
  • preferred particles of the invention having cores made up of clusters of crystals exhib it a remarkably high surface area per unit weight and a generally corresponding high coupling capacity, which indicates that such particles have an open or porous structure.
  • bioaffinity adsorbents can be covalently bonded to the organo-metallic coated magnetic particles of this invention by conventional coupling chemistries. Several coupling reactions can be performed. For example:
  • the ligand to be coupled contains an amino group, it can be coupled directly to the activated organo-metallic polymer. If a different functionality is desired, it can be introduced, for example, by adding a spacer arm containing the functionality by sequential reaction of the organo-metallic polymer (e.g., titanium- tetra-isopropoxide) with any omega-functional higher molecular weight alcohol. The amino group on the ligand can then be coupled to the free functional group on the spacer arm; or
  • the ligand contains an aldehyde group instead of an amino group, it can be coupled directly to the free amino group of an amino alkane (that is, an alkane spacer arm having an amino functionality) on the coated magnetic particle.
  • bioaffinity adsorbent is defined as any biological or other organic molecule capable of specific or nonspecific binding or interaction with another biological molecule, which binding or interaction may be referred to as "ligand/ligate " binding or interaction and is exemplified by, but not limited to, antibody/antigen, antibody/hapten, enzyme/substrate, carrier protein/substrate, lectin/carbohydrate, receptor/hormone, receptor/ effector or repressor/inducer bindings or interactions.
  • the coupled organo-metallic coated magnetic particles of the present invention can be used in immunoassays or other binding assays for the measurement of analytes in solution.
  • immunoassay is defined as any method for measuring the concentration or amount of an analyte in a solution based on the immunological binding or interaction of a polyclonal or monoclonal antibody and an antigen, which method (a) requires a separation of bound from unbound analyte; (b) employs a radioisotopic, fluorometrlc, enzymatic, chemiluminescent or other label as the means for measuring the bound and/or unbound analyte; and (c) may be described as
  • Immunoassays are exemplified by, but are not limited to, radioimmunoassays (RIA), immunoradiometric assays (IRMA), fluoroimmunoassays (FIA), enzyme immunoassays (EIA), and sandwich method Immunoassays.
  • the analyte or the bioaffinity adsorbent can include, for example, antibodies, antigens, haptens, enzymes, apoenzymes, enzymatic substrates, enzymatic inhibitors, cofactors, nucleic acids, binding proteins, carrier proteins, compounds bound by binding proteins, compounds bound by carrier proteins, lectins, monosaccharides, polysaccharides, hormones, receptors, repressors and inducers.
  • Such assays are preferably carried out by mixing a sample containing an unknown concentration of analyte with a known amount of labeled analyte in the presence of magnetic particles coupled to a bioaffinity adsorbent capable of binding to, or interacting with, both unlabeled and labeled analyte, allowing the binding or interaction to occur, magnetically separating the particles, measuring the amount of label associated with the magnetic particles and comparing the amount of label to a standard curve to determine the concentration of analyte in the sample.
  • binding assay or “non-immune assay” is defined as any method for measuring the concentration or amount of an analyte in solution based on the specific or nonspecific binding or interaction, other than antibody/ antigen binding or interaction, or a bioaffinity adsorbent and another biological or organic molecule, which method (a) requires a separation of bound from unbound analyte; (b) employs a radioisotopic, fluorometric, enzymatic, chemiluminescent or other label as as the means for measuring the bound and/or unbound analyte; and (c) may be described as “competitive” if the amount of bound measurable label is generally inversely proportional to the amount of analyte originally in solution or “non-competitive” if the amount of bound measurable label is generally originally in solution.
  • the magnetic organo -metallic - coated particles of this invention are useful in immobilized enzyme systems, particularly where enzyme recycling is desired.
  • immobilized enzyme system is defined as any enzymatically catalyzed biochemical conversion or synthesis or degradation wherein the enzyme molecule or active site thereof is not freely soluble but is adsorptively or covalently bound to a solid phase support, which support is suspended in or contacted with the surrounding medium and which may be reclaimed or separated from said method.
  • enzymatic reactions are carried out by dispersing enzyme- coupled magnetic particles in a reaction mixture containing one or more substrates, under conditions sufficient for the reaction between the enzyme and substrate to occur, magnetically separating the enzyme-magnetic particle from the reaction mixture containing products and unreacted substrates and, if desired, redispersing the particles in fresh substrates thereby reusing the enzyme.
  • affinity chromatography is defined as a method for separating, isolating, and/or purifying a selected molecule from its surrounding medium on the basis of its binding or interaction with a bioaffinity adsorbent adsorptively or covalently bound to a solid phase support, which support is suspended in or contacted with the surrounding medium and which may be reclaimed or separated from said medium by dispersing bioaffinity adsorbent coupled magnetic particles in solutions or suspensions containing molecules or cells to be isolated and/or purified, allowing the bioaffinity adsorbent and the desired molecules or cells to interact, magnetically separating the particles from the solutions or suspension and recovering the isolated molecules or cells from the magnetic particles.
  • the organo-metallic coated magnetic particles of this invention can be used in in vivo systems for the diagnostic localization of cells or tissues recognized by the particular bioaffinity adsorbent coupled to the particle and also for magnetically directed delivery of therapeutic agents coupled to the particles to pathological sites.
  • Magnetic separation times of less than about ten minutes can be achieved with magnetic particles of the invention by contacting a vessel containing a dispersion of the particles with a pole face of a permanent magnet no larger in volume than the volume of the vessel.
  • Magnetic separation time is defined to be the time for the turbidity of the dispersion to fall by 95 percent.
  • Example 1 Preparation of Superparamagnetic Magnetite Particles 200 grams (1.58 moles) of ferrous chloride (VWR Scientific) and 325 grams (2.0 moles) of ferric chloride were dissolved in 3 liters of water. 2000 grams of ammonium hydroxide (VWR Scientific) concentrate were added at a rate of 50 ml/minute under constant agitation, during which time the temperature of the solution was kept between 25 and 40°C. After the addition of the ammonium hydroxide was complete, the magnetic particle (Fe 3 O 4 ) aqueous slurry was allowed to cool to room temperature.
  • VWR Scientific ferrous chloride
  • VWR Scientific ammonium hydroxide
  • Example #3 The material was cooled to room temperature and used as a monomer in making the tetravalent titanium organo- metallic coating in Example #3.
  • Example 2 Preparation of Amine Functional Organo- titanate Coated Magnetic Particle According to the procedure s et out in Exampl e 1 , 4 moles FeCl 3 and 2 moles of FeCl 2 were dissolved in 4 L of distilled water and precipitated with 16 moles of ammonium hydroxide. The precipitate was washed 5 time s with water and 3 times with acetone. N,N-dimethyl formamlde (DMF) was added to the precipitate in the following ratio: 10 ml of DMF per gram of Fe 3 O 4 . The mixture was loaded into a Eiger Mill and mill e continuously for 10 minutes. The mixture was then transferred to a beaker and heated with stirring for 30 minutes at 100°C. The amine functional organo-titanate prepared in Example 2 was immediately added after preparation with constant stirring to the mixture in a ratio of 1 g dry Fe 3 O 4 per 3 g of amine functional organo-titanate.
  • DMF N,N-dimethyl formaml
  • Example 2 The procedure described in Example 2 was fo l lowe d except that the organo-titanate was reacted with a comixture of amino-functional hexanol and hexanol to produce a monomer having reduced amine functionality.
  • Hexanol and 6 -amino- 1 -hexanol in a molar ratio of 6:1 were mixed in a 50 ml beaker for one minute.
  • Tyzor TPT was added to the alcohol mixture in the ratio of 1 mole of alcohol per mole of Tyz or TPT.
  • the reaction mixture was s tirred for one minute , he ated to 70 ° C fo r 10 minutes to evaporate the isopropyl alcohol produced by the reaction and cooled to room temperature.
  • the resulting compound was an organotitanate, 6 - amino -hexyl-titanium- tri-isopropoxide having alternating non- functional hexyl groups, that is, hexyl chains lacking the amino group.
  • the weight ratios of 6 - amino - 1 -hexanol: Tyzor TPT:hexanol were 1:26:9.6.
  • This compound was used as a monomer to make an organo - titanium coating as described in Example 5.
  • Example 3 The procedure described in Example 3 was followed except that the amine-functional organo-titanate was the material prepared in Example 5.
  • the mixture of magnetic particles and organo-titanate monomer was heated to 95°C for one hour with constant stirring and milled in an
  • Eiger Mill for 4 minutes. The mixture was washed nine times with water. Adipic acid was added in the ratio of 0.5 moles of adipic acid per mole of total particles. One mole of carbodiimide (CDI) was added, and the mixture was mixed for 30 minutes on a ball mill. 1,6 hexane- diamine was added in the ratio of 0.5 moles of 1,6 hexane-diamine per mole of total particles. One mole of CDI was added and the mixture was mixed for 30 minutes. The resulting material was washed five times with water, the particles were collected using an external magnetic field of 2000 gauss and the aqueous waste was decanted.
  • CDI carbodiimide
  • Example 6 Preparation of Subdomain Magnetite Particles by Reaction of Particulate Ferrocene and Iron (II) Hydroxide
  • a slurry containing 20% ferrocene (by weight) (dicyclopentadenyliron; Strem Chemical Co., Newburyport, MA) in water was prepared by mixing the ferrocene with the water.
  • the slurry was added to a commercial ball mill. The mill was filled halfway with 1 ⁇ 4 " stainless steel balls and the slurry was milled for a period of 2 hours.
  • a second ferrous hydroxide slurry (iron (II) hydroxide) was made according to the following procedure.
  • An aqueous solution containing 20g of ferrous sulfate (VWR Scientific) was precipitated using 50g of ammonium hydroxide concentrate to form gelatinous ferrous hydroxide.
  • the gel was filtered and the filtrate washed with 5 to 100g volumes of water. The washed gel was then made into a 10% aqueous slurry and milled as previously described for 5 hours.
  • the ferrocene and hydroxide slurries were mixed, and the mixture was milled for one day to form fine Fe 3 O 4 particles.
  • the particles were about 100 A in diameter and were responsive to a magnetic field. These particles can be coated as described in Examples 2-5 above.
  • Example 7 Preparation of Subdomain Nickel-Ferrite Particles
  • Subdomain nickel-ferrite particles were prepared according to the procedure set out in Example 6, except that a mixture of 50g a 20% nickelocene slurry (dicyclopentadenylnickel; Strem Chemical Co., Newburyport, MA) and 50g of a 20% ferrocene slurry were used in lieu of the 100g of the ferrocene slurry in Example 6.
  • Magnetically responsive nickel-ferrite particles having a particle size of about 100 A were produced by this method.
  • Example 8 Preparation Subdomain Cobat- Ferrite Particles
  • Subdomain cobalt - ferrite particles were prepared according to the procedure set out in Example 6, except that a mixture of 50g of a 20% (by wt.) cobaltocene slurry (dicyclopentadenylcobalt; Strem Chemical Co., Newburyport, MA ) and 50g of the ferrocene slurry were used in lieu of 100g of the ferrocene slurry in Example 6.
  • Magnetically responsive cobalt-ferrite particles having a particle size of about 100 A were produced by this method.
  • Example 9 Preparation of Subdomain Metal Particles by Sodium Borohydride Reduction and Size Reduction by Milling 200 gm (1.58 moles) of ferrous chloride was dissolved in 1 liter of water. 500 gm of dry sodium borohydride were added to the solution to form a fine iron powder precipitate. The precipitate was washed with water and collected by filtration. The filtered powder was resuspended in water and re-filtered. The washing procedure was done 4 additional times. On the final suspension, the slurry was adjusted to a concentrate of 20% and milled as described in Example 6 for a period of 75 days to produce particles with a mean diameter of less than 50 A.

Abstract

L'invention concerne des particules à sensibilité magnétique ainsi que leur utilisation dans des systèmes où la séparation de certaines molécules du milieu environnant est nécessaire ou désirable. Les particules magnétiques consistent en un noyau métallique, d'oxyde métallique ou d'alliage métallique revêtues d'un polymère organo-métallique auquel est rattachée une fonctionnalité organique à laquelle une variété de molécules organiques et/ou biologiques peuvent être couplées. Les particules peuvent être dispersées dans des milieux aqueux sans décantation rapide par gravité et récupérées des milieux aqueux en utilisant un champ magnétique. Les particules à sensibilité magnétique de l'invention peuvent être couplées à des molécules biologiques ou organiques avec une affinité pour certaines autres molécules biologiques ou organiques, ou avoir la capacité d'en adsorber ou pouvant avoir une interaction avec certaines autres molécules biologiques ou organiques. Des particules ainsi couplées peuvent être utilisées dans une variété de systèmes in vitro ou in vivo impliquant des étapes de séparation ou le mouvement dirigé des molécules couplées vers des sites particuliers, y compris des analyses immunologiques, d'autres analyses biologiques, des réactions biochimiques ou enzymatiques, des purifications chromatographiques par affinité, le triage de cellules et des utilisations diagnostiques et thérapeutiques.The invention relates to particles with magnetic sensitivity and their use in systems where the separation of certain molecules from the surrounding medium is necessary or desirable. The magnetic particles consist of a metallic core, metallic oxide or metallic alloy coated with an organometallic polymer to which is attached an organic functionality to which a variety of organic and / or biological molecules can be coupled. The particles can be dispersed in aqueous media without rapid decantation by gravity and recovered from aqueous media using a magnetic field. The magnetic sensitivity particles of the invention can be coupled to biological or organic molecules with an affinity for certain other biological or organic molecules, or have the capacity to adsorb them or which can have an interaction with certain other biological or organic molecules. Particles so coupled can be used in a variety of in vitro or in vivo systems involving separation steps or the directed movement of coupled molecules to particular sites, including immunoassays, other bioassays, biochemical reactions or enzymatic, affinity chromatographic purifications, cell sorting and diagnostic and therapeutic uses.

Description

ORGANO- METALLI C C OAT ED PART I CLE S FOR US E IN S EPARATI ONS
Description
Background of the Invention Magnetic separations in biological systems have been used as an alternative to gravitational or centrifugal separations. B.L., Hirschbein, et al ., Chemtech, pp.
172-179 (1982); M. Pourfarzaneh, The Ligand Quarterly,
5(1) :41-47 (1982); and P.J., and P., Dunhill, Enzyme Microb. Technol. 2 : 2-10 (1980). There are several advantages to using magnetically separable particles as supports for biological molecules such as enzymes, antibodies and other bioaffinity adsorbents. For example, when magnetic particles are used as solid phase supports in immobilized enzyme systems, the enzyme can be selectively recovered from the media, including media containing suspended solids, allowing recycling in enzyme reactors. P.J., Robinson, et al . , Biotech. Bioeng.,
15:603-606 (1973). When used as solid supports in immunoassays or other competitive binding assays, magnetic particles permit the reaction to occur under homogeneous conditions, which promotes optimal binding kinetics, minimally alters analyte-adsorbent equilibrium and facilitates separation of bound from unbound analyte, particularly as compared to centrifugation.
Centrifugal separations are time-consuming, require expensive and energy-consuming equipment and pose radiological, biological and physical hazards. Magnetic separations are relatively rapid and easy, requiring simple equipment. The use of non-porous adsorbent- coupled magnetic particles in affinity chromatography systems allows better mass transfer and results in less fouling of the sample than in conventional affinity chromatography systems.
The practical development of magnetic separations has been hindered by several critical properties of the magnetic particles developed thus far. For example, large magnetic particles (e.g., having a mean diameter in solution greater than 10 microns) respond to weak magnetic fields and magnetic field gradients; however, they tend to settle rapidly, limiting their usefulness for reactions requiring homogeneous conditions. Large particles also have a more limited surface area per weight than smaller particles, so that less material can be coupled to them. Examples of large particles are those described by Robins on et al., in Biotech . Bioeng., 15:603-606 (1973), which are 50-125 microns in diameter; particles described by Mosbach and Anderson in Nature, 270:259-261 (1977), which are 60-140 microns in diameter and those described by Guesdon et al., in J. Allergy
Clin. Immunol., 61(1): 23-27 (1978) which are 50-160 microns in diameter. Smaller magnetic particles have been described. For example, composite particles described by Hersh and Yaverbaum, in U.S. Patent No. 3,933,997, are ferromagnetic iron oxide (Fe3O4) carrier particles, which we re reported to have diameters between 1.5 and 10 microns.
However, based on the reported settling rate of 5 minut e s and coupling capacity of only 12 milligrams of protein per gram of particles, the actual size of the particles in solution is expected to be substantially greater than 10 microns. L.S. Hersh and S. Yaverbaum, C l in . Chem.
Acta, 63:69-72 (1975).
Small magnetic particles (e.g., having a mean diameter in solution less than about 0.03 microns) can be kept in solution by thermal agitation and do not tend to settle spontaneously. However, the magnetic field and magnetic field gradient required to remove such particles from solution are large and require heavy and bulky magnets for generating these fields, which are inconvenient to use in bench top work. Magnets capable of generating magnetic fields in excess of 5000 Oersteds, for example, are typically required to separate magnetic particles of less than 0.03 microns in diameter.
The ferromagnetic carrier particles must generally be coated in order to provide a reactive substrate for attaching chemical functional groups to bind enzymes or antibodies, for example. Silane polymers are often used for this purpose. Particles described in U.S. Patent No. 3,933,997 are coated with silanes capable of reacting with anti-digoxin antibodies to chemically couple the antibodies to the carrier particles. Various silane couplings are discussed in U.S. Patent No. 3,652,761, which is hereby incorporated by reference. Procedures for silanization known in the art generally differ from each other in the media chosen for the polymerization of silane and its disposition on reactive surfaces. The medium is generally an organic solvent such as toluene (H.W., Weetall, In: Methods of Enzymology, K. Mosbach (ed), 44:134-148, 140 (1976)), methanol (U.S. Patent No. 3,933,997) or chloroform (U.S. Patent No. 3,652,761). Silane depositions from aqueous alcohol and aqueous solutions with acid have also been used. H.W. Weetall, In: Methods in Enzymology, supra, p.139 (1976).
There are several drawbacks to silane-coated particles. For example, the dehydration methods used to dry the coatings, such as air and/or oven drying, allow the silanized surfaces of the carrier particles to contact each other, potentially resulting in interparticle bonding, including cross-linking between particles by siloxane formation, van der Waals interactions or physical adhesion between adjacent particles. This interparticle bonding yields covalently or physically bonded aggregates of silanized carrier particles of considerably larger diameter than individual carrier particles. Such aggregates have low surface area per unit weight and hence, a low capacity for coupling with molecules such as antibodies, antigens or enzymes. Such aggregates also have gravitational settling times which are too short for many applications.
Magnetic particles capable of binding bioaffinity reagents are useful in separating desired biological components from a sample, for example, in radioimmunoassay. Radioimmunoassay (RIA) is a term used to describe methods for analyzing the concentrations of substances involving a radioactively labeled substance which binds to an antibody. The amount of radioactivity bound is altered by the presence of an unlabeled test substance capable of binding to the same antibody. The unlabeled substance, if present, competes for binding sites with the labeled substance and thus decreases the amount of radioactivity bound to the antibody. The decrease in bound radioactivity can be correlated to the concentration of the unlabeled test substance by means of a standard curve. An essential step of RIA is the separation of bound and free label which must be accomplished in order to quantitative the bound fraction.
A variety of conventional separation approaches have been applied to RIA including coated tubes, particulate systems, and double antibody separation methods. Coated tubes, such as described in U.S. Patent No, 3.646,346 allow separation of bound and free label without centrifugation but suffer from two major disadvantages. First, the surface of the tube limits the amount of antibody that can be employed in the reaction. Second, the antibody is far removed (as much as 0.5 cm) from the antigen, slowing the reaction between the antibody and antigen. G.M. Parsons, In: Methofd in Enzymology , J.F. Langone (ed), 73:225 (1981); P.N. Nayak, The Ligand Quarterly, 4(4) :34 (1981).
Antibodies have been attached to particulate systems to facilitate separations. U.S. Patent Nos. 3,652,761 and 3,555,143. Such systems have large surface areas permitting nearly unlimited amounts of antibody to be used, but the particulates frequently settle during the assay. The tube frequently must be agitated to achieve even partial homogeneity P.M. Jacobs, The Ligand Quarterly, 4(4): 23-33 (1981). Centrifugation is still required to effect complete separation of bound and free label.
Antibodies may react with labeled and unlabeled molecules followed by separation using a second antibody raised to the first antibody. The technique, termed the doubled antibody method, achieves homogeneity of antibody during reaction with label but requires an incubation period for reaction of first and second antibodies followed by a centrifugation to pellet the antibodies.
Antibodies have been attached to magnetic supports in an effort to eliminate the centrifugation steps in radioimmunoassays for nortriptyline, methotrexate, digoxin, thyroxine and human placental lactogen. R.S. Kamel et al., Clin. Chem., 25 (12): 1997 - 2002 (1979); R.S. Kamel and J. Gardner, Clin. Chem. Acta., 89:363-370 (1978); U.S. Patent No., 3,933,997; C. Dawes and J. Gardener, Clin.Chem.Acts, 86:353-356 (1978); D.S.
Ithakissios et al., Clin. Chem. Acta., 84 :69-84 (1978);
D.S. Ithakissios and D.O. Kubiatowicz, Clin. Chem.,
23(11):2072-2079 (1977); and L. Nye et al., Clin.Chem. Acta., 69:387-396 (1976), the teachings of the above are hereby Incorporated by reference. Such methods suffer from large particle sizes (10-100 microns in diameter) and require agitation to keep the antibody dispersed during the assay. Since substantial separation occurs from spontaneous settling in the absence of a magnetic field these previous methods are in fact only magnetically assisted gravimetric separations. Davies and Janata in U.S. Patent No. 4 , 177 , 253 employed magnetic materials such as hollow glass or polypropylene (4-10 microns in diameter) with magnetic coatings (2 microns 10 microns thick) covering a proportion of the particle surface. Antiestradiol antibodies were coupled to such particles and their potential usefulness in estradiol RIAs was demonstrated. While this approach may have over come the problem of settling, the particle size and the magnetic coating nonetheless present limitations on surface area and hence limitations on the availability of sites for antibody coupling.
Magnetic separations have been applied in other biological systems besides RIA. Several nonisotopic immunoassays, such as fluoroimmunoassays (FIA) and enzyme-immunoassays (EIA) have been developed which employ antibody-coupled (or antigen coupled) magne t i c particles. The principle of competitive binding is the same in FIA and EIA as in RIA except that fluorophores and enzymes, respectively, are submitted for radioiso- topes as label. By way of illustration, M. Pourfarzaneh et al., and R.S. Kamel et al., developed magnetizable solid-phase FIA's for cortisol and phenyltoin, respectively, utilizing ferromagnetic cellulose/iron oxide particles to which antibodies were coupled by cyanogen bromide activation. M. Pourfarzaneh et al . , C l in. Chem. ,
26(6):730-733 (1980); R.S. Kamel et al., Clin. Chem., 26(9):1281-1284 (1980).
A non-competitive solid phase sandwich technique EIA for the measurement of IgE was described by J.L. Guesdon et al., in J. Allergy Clin. Immunol., 61(1) :23-27 (1978). By this method, anti-IgE antibodies coupled by glutaraldehyde activation to magnetic polyacrylamide agarose beads are incubated with a test sample containing IgE to allow binding. Bound IgE is quantitated by adding a second anti-IgE antibody labeled with either alkaline phosphatase or β-galactosidase. The enzyme labeled second antibody complexes with IgE bound to the first antibody, forming the sandwich, and the particles are separated magnetically. Enzyme activity associated with the particles, which is proportional to bound IgE is then measured permitting IgE quantitation.
A magnetizable solid phase non-immune radioassay for vitamin B12 has been reported by D.S. Ithakissios and D.O. Kubiatowicz Clin. Chem., 23(11) : 2072 - 2079 (1977). The principle of competitive binding in non-immune radioassays is the same as in RIA with both assays employing radioiso topic labels. However, while RIA is based on the binding or interaction of certain biomolecules like vitamin B12 with specific or non-specific binding, carrier, or receptor proteins. The magnetic particles of Ithakissios and Kubiatowicz were composed of barium ferrite particles embedded in a water-insoluble protein matrix.
In addition to their use in the solid phase biological assays just described, magnetic particles have been used for a variety of other biological purposes. For example, magnetic particles have been used in cell sorting systems to isolate select viruses, bacteria and other cells from mixed populations. U.S. Patent Nos., 3,970,518; 4,230,685; and 4,267,234, the teachings of which are hereby incorporated by reference. They have been used in affinity chromatography systems to selectively isolate and purify molecules from solution and are particularly advantageous for purification from colloidal suspensions. K. Mosbach and L. Anderson, Nature 170:259-261 (1977), hereby incorporated by reference. Magnetic particles have also been used as the solid phase support immobilized enzyme systems. Enzymes coupled to magnetic particles are contacted with substrates for a time sufficient to catalyze the biochemical reaction. Thereafter, the enzyme can be magne- tically separated from products and unreacted substrate and potentially can be reused. Magnetic particles have been used as supports for α-chymotrypsin, β -galactos idase (U.S. Patent No. 4,152,210), hereby incorporated by reference) and glucose isomerase (U.S. Patent No. 4,343,901, hereby incorporated by reference) in immobilized enzyme systems.
Summary of the Invention
The present invention relates to magnetically responsive particles coated with an organo-metallic polymer capable of binding bioaffinity adsorbents, and to their use in the separation of biological molecules from, or directed movement of the molecules in, the surrounding medium. The organo-metallic coating is adsorbed onto or covalently bound to the magnetic particle. Methods and compositions for preparing and using organo-metallic coated magnetic particles are provided.
The magnetic particles comprise a magnetically responsive metal, metal alloy, or metal oxide core surrounded by an organo-metallic polymer coating which is adsorbed or covalently bound to the particle. The organo-metallic polymer is formed from an organo-metallic monomer, which is applied to the metal particle, and thermally cross-linked in situ to form an adsorbed or a covalently bound polymer coating. Organo-titanium polymers are preferred, however, organo-metallic polymers formed from coordinate complexes of other transition metals, such as zirconium (Zr), hafnium (Hf), vanadium (V), tantalum (Ta) and niobium (Nb), or post-transition metals, such as tin (Sn) and antimony (Sb), can be used. A wide variety of bioaffinity adsorbents can be covalently bonded to the organo-metallic polymer coating through selected coupling chemistries.
More particularly, the invention relates to methods for the preparation of magnetically responsive particles comprising a metal, metal alloy or metal oxide core and an organo-metallic coating having an aliphatic moiety and an organic functionality to which a variety of organic and/or biological molecules can be coupled. The particles, coupled or uncoupled, can be dispersed in aqueous media forming a colloidal dispersion which is stable, that is, the particles resist rapid gravitational settling. The particles can be reclaimed from the media by applying a magnetic field.
Preferably, the particles are superparamagnetic; that is, they exhibit no reminent magnetization after removal of a magnetic field which allows the particles to be redispersed without magnetic aggregate formation.
The organo-metallic coated magnetically responsive particles of the invention may be coupled through the organic functionality to biological or organic molecules with affinity for, or the ability to adsorb, or which interact with, certain other biological or organic molecules. Particles so coupled may be used in a variety of in vitro or in vivo systems involving s ep arat i ons steps or the directed movement of coupled molecules to particular sites, including immunological assays, other biological assays, biochemical or enzymatic reactions, affinity chromatographic purification, cell sorting and diagnostic and therapeutic uses. The present organo-metallic coated magnetic particles provide superior composition, size, surface area, coupling versatility, settling properties and magnetic behavior for use in biological separations. The magnetic particles of this invention are suitable for many of the assays, enzyme immobilization, cell sorting and affinity chromatography procedures reported in the literature and, in fact, overcome many of the problems associated with particle settling and reuse experienced in the past with such procedures.
Detailed Description of the Invention
The magnetically responsive particles of this invention overcome problems associated with the size, surface area, gravitational settling rate and magnetic character of previously developed magnetic particles. Gravitational settling times in excess of about 24 hours can be achieved with the present magnetic particles. The gravitational settling time is defined to be the time for the turbidity of a dispersion of particles to fall by fifty percent in the absence of a magnetic field gradient. The present magnetic particles comprise a core of a magnetically responsive metal, metal alloy or metal oxide, coated with organo-metallic polymer, which is capable of binding reactive groups or agents, for example, chemically reactive groups, biologically reactive groups or bioaffinity agents. The organo- metallic polymer is adsorbed onto or covalently bound to the magnetic particle. The term "magnetically responsive particle" or "magnetic particle" is defined as any particle dispersible or suspendible in aqueous media without significant gravitational settling, and separable from suspension by application of a magnetic field.
The term "magnetic core" is defined as a crystal or group (or cluster) of crystals of a transition metal, alloy or magnetic metal oxide having ferrospinel structure and comprising trivalent and divalent cations of the same or different transition metals or magnetic metal crystal group. Metals, alloys and oxides which are useful as magnetic core material in the present invention include the metals, alloys and oxides based on metals which appear in the Periodic Table in Groups 4a and b, 5a and b, 6a and 7a. These include, for example, divalent transition metals, such as iron, magnesium, manganese, cobalt, nickel, zinc and copper, alloys of these metals such as iron alloys or oxides (e.g., iron magnesium oxide, iron manganese oxide, iron cobalt oxide, iron nickel oxide, iron zinc oxide and iron copper oxide), cobalt ferrite, samarium cobalt, barium ferrite, and aluminum - ni ckel - c ob al t and metal oxi de s inc luding magnetite (Fe3O4 ), hematite (Fe2O3) and chromium dioxide (CrO2). By way of illustration, a magnetic core may be comprised of a cluster of superparamagnetic crystals of iron oxide, or a cluster of superparamagnetic or ferromagnetic crystals of irons or oxide, or may consist of an single superparamagnetic or ferromagnetic crystal of an iron oxide or metal alloy.
The present particles are preferably between about 0.003 and about 1.5 microns in diameter, and have a surface area of from about 50 to 150 meters/gm, which provides a high capacity for coupling of a bioaffinity adsorbent, chemical or biochemical reactive group.
Magnetic particles of this size range overcome the rapid settling problems of larger particles, but obviate the need for large magnets to generate the magnetic fields and magnetic field gradients required to separate smaller particles. For example, magnets used to effect separations of the magnetic particles of this invention need only generate magnetic fields between about 100 and about 1000 Oersteds. Such fields can be obtained with permanent magnets which are smaller than the container which holds the dispersion of magnetic particles and, thus, are suitable for benchtop use.
Particles with superparamagnetic behavior are preferred since superparamagnetic particles do not exhibit the magnetic aggregation associated with ferromagnetic particles and permit redispersion and reuse. The term "superparamagnetism" is defined as that magnetic behavior exhibited by iron, cobalt, nickel or other metal alloys or metal oxides having a crystal size of less than about 300A, which behavior is characterized by responsiveness to a magnetic field without reminant magnetization.
Ferromagnetic particles may be useful in certain applications of the Invention. The term "ferromagnetism" is defined as that magnetic behavior exhibited by Iron, iron alloys or iron oxides with a crystal size greater than about 500A, which behavior is characterized by responsiveness to a magnetic field with a reminant magnetization of greater than about 10 gauss upon removal of the magnetic field.
The particles or crystals are then coated with an organo-metallic monomer material capable of adsorptive or covalently bonding to the magnetic particles. Organometallic monomers useful for the present coated particles are organic coordinate complexes of selected transition and/or post transition metals which are capable of forming a stable coordination coumpound, and organic ligands, which can be adsorbed onto or covalently bound to the magnetic particle and, crosslinked in situ on the particle surface, thereby forming the organo-metallic polymer coating. The organo-metallic monomer must be able to be functionalized or derivatized in a manner that allows the polymer formed therefrom to form covalent bonds with bioaffinity or chemical affinity adsorbents. For this purpose, the organo-metallic polymer is post- functionalized or derlvitized with an aliphatic "spacer arm" which is terminated with an organic functional group capable of coupling with bioaffinity adsorbents. The "spacer arm" is an aliphatic hydrocarbon having from about 2 to about 60 atoms, e.g., carbon, nitrogen and/or oxygen atoms. The purpose of the spacer arm is to provide a non-reactive linker (or spacer) between the organic group which reacts with the chemical group, biochemical group or bioaffinity adsorbent and the polymer chain, and to impart an appropriate degree of hydrophilic/hydrophobic balance to the surface of the coated particle. The organic group is generally a reactive group such as an amine (NH2), carboxyl group (COOH), cyanate (CN), phosphate (PO3H), sulfate (SO3H), thiol (SH), hydroxyl (OH) group, vinyl (C=C), nitrate (NO2), aldehyde, epoxide, succinamide or anhydride group coupled to an aliphatic or aromatic moiety.
Particularly useful organo-metallic compounds are coordinate complexes formed from selected transition metals (e.g., Ti, Zr, Hf, V, Zn, Cd, Mn, Te, Re, Ta, Nb) and/or post-transition metals (e.g., Sn, Sb, Al, Ga, In, Ge). Organo-titanium compounds are parti cul ar ly preferred. Organo-titanium compounds which are us e ful including, for example, titanium - tetra - isopropoxide, amino - hexyl - titanium - tri - isopropoxide, amino-propyl- titanium - tri - isopropoxide and carboxyl -hexyl - titanium- tri - isopropoxide. In one embodiment of the present invention, amino -hexyl - titanium- tri - isoproxide is coated onto the magnetic particle of choice, and thermally crosslinked to form an organo-titanium polymer coating having an aliphatic spacer arm (the hexyl moiety) and organic functional group (the amine group).
The coated particle is post-functionalized, if necessary, in a manner that allows the organo-metallic polymer to form covalent bonds with bioaffinity or chemical affinity adsorbents. In one embodiment of the present method, an organo-titanium polymer, such as titanium- tetra- isopropoxide which lacks the spacer arm and organic functional group, is coated onto the magnetic particle of choice and partly crosslinked at about 40°C for a period of time sufficient to allow the organotitanium polymer to become adsorbed onto the particle surface. The organotitanium coated magnetic particle is then activated by reaction with an agent such as 1-hydroxy- 6-amino hexane, to form the amino-hexyl- titanium- tri- isopropoxide. The coating is then crosslinked at elevated temperatures to form an organotitanium polymer coating having an aliphatic spacer arm and an organic functionality (i.e., the amine group). The functionalized particle can then be reacted or coupled, with the bioaffinity adsorbent of choice. The magnetic core particles are prepared according to the following general procedure: metal salts are precipitated in a base to form fine magnetic metal oxide crystals. The crystals are redlspersed, then washed in water and in an electrolyte. Magnetic separation can be used to collect the crystals between washes if the crystals are superparamagnetic.
In one embodiment of the present invention, superparamagnetic iron oxide particles are made by precipitation of divalent (Fe2+ ) and trivalent (Fe3+ ) iron salts, for example, ferrous ammonium sulfate, Fe2(NH2)(SO4) and ferric sulfate, Fe2(SO4)3, in aqueous base. The ratio of Fe2+ and Fe3+ and counterion can be varied wi thout substantial changes in the final product by increasing the amount of Fe2+ while maintaining a constant molar amount of iron. Counterions including nitrate, sulfate, chloride or hydroxide are useful in the method. A Fe2+/Fe3+ ratio of about 2:1 to about 4:1 is useful in the present invention; a ratio of about 2:1 Fe2+ : Fe3+ is particularly useful. An Fe2+ /Fe3+ ratio of 1:1 produces magnetic particles of slightly inferior quality to those resulting from the higher Fe2+ /Fe3+ ratios, the particle size is more heterogeneous than that resulting from Fe3+ /Fe2+ of 2:1 or 4:1.
In this embodiment, aqueous solutions of the iron salts are mixed in a base, such as ammonium, sodium or potassium hydroxide, which results in the formation of a crystalline precipitate of superparamagnetic iron oxide. The precipitate is washed repeatedly with water by magnetically separating and redispersing it until a neutral pH is reached. The precipitate is then washed with about five equal portions of a water miscible solvent, such as acetone, methanol or ethanol that has been dried over molecular sieves to remove all of the water.
The repeated use of magnetic fields to separate the iron oxide from suspension during the washing steps is facilitated by the superparamagnetic properties of the crystals. Regardless of how many times the particles are subjected to magnetic fields, they never become magnetically agglomerated and consequently, can be redispersed by mild agitation. Ferromagnetic particles cannot be prepared by this washing procedure as they tend to magnetically aggregate after exposure to magnetic fields and cannot be homogeneously redispersed.
Other divalent transition metal salts such as magnesium, manganese, cobalt, nickel, zinc and copper salts may be substituted for iron salts in the precipltation or milling procedure to yield magnetic metals or metal oxides. For example, the substitution of divalent cobalt chloride (CoCl2) for FeCl2 in the above procedure produced ferromagnetic metal oxide particles. Ferromagnetic metal oxide particles such as those produced with CoCl2 can be washed in the absence of magnetic fields by employing conventional techniques of centrifugation or filtration between washings to avoid magnetizing the particles. As long as the resulting ferromagnetic metal oxides are of sufficiently small diameter to remain dispersed in aqueous media, they can also be coated with the organo-metallic polymer and coupled to bioaffinity adsorbents for use in systems requiring a single magnetic separation, e.g., certain radioimmunoassays. Ferromagnetism limits particle usefulness in those applications requiring redispersion or reuse.
In another embodiment of the present invention, the magnetic core particles can be made by precipitating metal powders and reducing the particle size by milling the resulting precipitate, for example, in a ball mill.
In this process, the metal powder is precipitated from an aqueous solution of, for example, Fe+2 or Fe+3 salt with sodium borohydride. For example, an aqueous solution of ferrous chloride (FeCl2) is mixed with sodium borohydride
(NaBH4) to form a fine iron precipitate. The resulting properties of the metal powder are unaffected by the valance of the counter ion or iron metal salt selected.
Complete precipitation occurs spontaneously upon borohydride addition. The magnetic metal powder is then collected by filtration and washed with about five equal volumes of water to remove all soluble salts, then washed with five equal volumes of dry in acetone to remove all residual water. The particle is added as an aqueous slurry in a concentration of about 1-25% to a c omme rc i al ball mill filled half way with 1/4" stainless steel balls and milled for 3-30 days. At the completion of the milling period, a superparamagnetic metal slurry is formed and coated and functionalized as the superparamagnetic particles described in the previous section.
In another embodiment of the present invention, the magnetic core particles are made by reacting a metallocene, e.g., particulate ferrocene (dicyclopentadenyliron, C10H10 Fe) with iron (II) hydroxide. In this embodiment, an aqueous ferrocene (or other metallocene) slurry is prepared, and an aqueous slurry of Iron (II) hydroxide is prepared separately. The ferrocene slurry is prepared, for example, by milling a mixture of ferrocene and water in a ball mill. The iron (II) hydroxide slurry can be prepared, for example, by precipitating an aqueous solution of ferrous sulfate with ammonium hydroxide to form ferrous hydroxide. The two slurries are then combined and milled, for example, forming fine magnetite particles. Other metallocene compounds (e.g., nickelocene, cobaltocene) can be mixed with the ferrocene to produce various magnetic ferrite particles. This process is described in detail in co-pending U.S. patent application Serial No. _________,
[Attorney's Docket No. OQC90-02] by M.S. Chagnon, filed concurrently herewith, the teachings of which are hereby incorporated herein by reference. In one embodiment of the present invention, the coating around the magnetic core particle is amino-pro- pyl- titanium- tri- isopropoxide. The polymerization is performed by redispersing the magnetic particle in an acetone solution, adding the organo-titanium monomer, then crosslinking with heat. The terms "coupled magnetically responsive particle" or "coupled magnetic particle" refer to any magnetic particle to which one or more types of bioaffinity adsorbents are coupled by covalent bonds, which covalent bonds may be amide, ester, ether sulfonamide, disulfide, azo or other suitable organic linkages depending on the functionalities available for bonding on both the coating of the magnetic particle and the bioaffinity adsorbents. Preferred magnetically responsive particles of the present Invention have metal oxide cores composed of clusters of superparamagnetic crystals affording efficient separation of the particles in low magnetic fields (100-1000 Oersteads) while maintaining super- paramagnetic properties. Aggregation of particles is controlled during particle synthesis to produce particles which are preferably small enough to avoid substantial gravitational settling over times sufficient to permit dispersions of the particles to be used in an intended biological assay or other application. The advantage of having superparamagnetic cores in magnetically responsive particles is that such particles can be repeatedly exposed to magnetic fields. Superparamagnetic particles do not exhibit reminent magnetization and have no coercive strength, and, therefore, do not ma gne ti c al ly aggregate, thus, the particles can be redispersed and reused. Even after coating, preferred particles of the invention having cores made up of clusters of crystals exhib it a remarkably high surface area per unit weight and a generally corresponding high coupling capacity, which indicates that such particles have an open or porous structure.
The bioaffinity adsorbents can be covalently bonded to the organo-metallic coated magnetic particles of this invention by conventional coupling chemistries. Several coupling reactions can be performed. For example:
(a) If the ligand to be coupled contains an amino group, it can be coupled directly to the activated organo-metallic polymer. If a different functionality is desired, it can be introduced, for example, by adding a spacer arm containing the functionality by sequential reaction of the organo-metallic polymer (e.g., titanium- tetra-isopropoxide) with any omega-functional higher molecular weight alcohol. The amino group on the ligand can then be coupled to the free functional group on the spacer arm; or
(b) If the ligand contains an aldehyde group instead of an amino group, it can be coupled directly to the free amino group of an amino alkane (that is, an alkane spacer arm having an amino functionality) on the coated magnetic particle.
The term "bioaffinity adsorbent" is defined as any biological or other organic molecule capable of specific or nonspecific binding or interaction with another biological molecule, which binding or interaction may be referred to as " ligand/ligate " binding or interaction and is exemplified by, but not limited to, antibody/antigen, antibody/hapten, enzyme/substrate, carrier protein/substrate, lectin/carbohydrate, receptor/hormone, receptor/ effector or repressor/inducer bindings or interactions. The coupled organo-metallic coated magnetic particles of the present invention can be used in immunoassays or other binding assays for the measurement of analytes in solution. The term " immunoassay" is defined as any method for measuring the concentration or amount of an analyte in a solution based on the immunological binding or interaction of a polyclonal or monoclonal antibody and an antigen, which method (a) requires a separation of bound from unbound analyte; (b) employs a radioisotopic, fluorometrlc, enzymatic, chemiluminescent or other label as the means for measuring the bound and/or unbound analyte; and (c) may be described as
"competitive" if the amount of bound measurable label is generally inversely proportional to the amount of analyte originally in solution or "non-competitive" if the amount of bound measurable label is generally directly proportional to the amount of analyte originally in the solution. Label may be in the antigen, the antibody, or in double antibody methods, the second antibody. Immunoassays are exemplified by, but are not limited to, radioimmunoassays (RIA), immunoradiometric assays (IRMA), fluoroimmunoassays (FIA), enzyme immunoassays (EIA), and sandwich method Immunoassays. The analyte or the bioaffinity adsorbent can include, for example, antibodies, antigens, haptens, enzymes, apoenzymes, enzymatic substrates, enzymatic inhibitors, cofactors, nucleic acids, binding proteins, carrier proteins, compounds bound by binding proteins, compounds bound by carrier proteins, lectins, monosaccharides, polysaccharides, hormones, receptors, repressors and inducers.
Such assays are preferably carried out by mixing a sample containing an unknown concentration of analyte with a known amount of labeled analyte in the presence of magnetic particles coupled to a bioaffinity adsorbent capable of binding to, or interacting with, both unlabeled and labeled analyte, allowing the binding or interaction to occur, magnetically separating the particles, measuring the amount of label associated with the magnetic particles and comparing the amount of label to a standard curve to determine the concentration of analyte in the sample.
The term "binding assay" or "non-immune assay" is defined as any method for measuring the concentration or amount of an analyte in solution based on the specific or nonspecific binding or interaction, other than antibody/ antigen binding or interaction, or a bioaffinity adsorbent and another biological or organic molecule, which method (a) requires a separation of bound from unbound analyte; (b) employs a radioisotopic, fluorometric, enzymatic, chemiluminescent or other label as as the means for measuring the bound and/or unbound analyte; and (c) may be described as "competitive" if the amount of bound measurable label is generally inversely proportional to the amount of analyte originally in solution or "non-competitive" if the amount of bound measurable label is generally originally in solution.
The magnetic organo -metallic - coated particles of this invention are useful in immobilized enzyme systems, particularly where enzyme recycling is desired. The term "immobilized enzyme system" is defined as any enzymatically catalyzed biochemical conversion or synthesis or degradation wherein the enzyme molecule or active site thereof is not freely soluble but is adsorptively or covalently bound to a solid phase support, which support is suspended in or contacted with the surrounding medium and which may be reclaimed or separated from said method. In this embodiment, enzymatic reactions are carried out by dispersing enzyme- coupled magnetic particles in a reaction mixture containing one or more substrates, under conditions sufficient for the reaction between the enzyme and substrate to occur, magnetically separating the enzyme-magnetic particle from the reaction mixture containing products and unreacted substrates and, if desired, redispersing the particles in fresh substrates thereby reusing the enzyme.
Affinity chromatography separations and cell sorting can be performed using the magnetic particles of this invention. The term "affinity chromatography" is defined as a method for separating, isolating, and/or purifying a selected molecule from its surrounding medium on the basis of its binding or interaction with a bioaffinity adsorbent adsorptively or covalently bound to a solid phase support, which support is suspended in or contacted with the surrounding medium and which may be reclaimed or separated from said medium by dispersing bioaffinity adsorbent coupled magnetic particles in solutions or suspensions containing molecules or cells to be isolated and/or purified, allowing the bioaffinity adsorbent and the desired molecules or cells to interact, magnetically separating the particles from the solutions or suspension and recovering the isolated molecules or cells from the magnetic particles.
It is further contemplated that the organo-metallic coated magnetic particles of this invention can be used in in vivo systems for the diagnostic localization of cells or tissues recognized by the particular bioaffinity adsorbent coupled to the particle and also for magnetically directed delivery of therapeutic agents coupled to the particles to pathological sites. Magnetic separation times of less than about ten minutes can be achieved with magnetic particles of the invention by contacting a vessel containing a dispersion of the particles with a pole face of a permanent magnet no larger in volume than the volume of the vessel. Magnetic separation time is defined to be the time for the turbidity of the dispersion to fall by 95 percent.
Furthermore, the use of functionalized organo- metallic polymers as the coating surrounding the metal oxide core of the magnetic particles described herein make possible the coupling of a wide variety of molecules under an equally wide variety of coupling conditions compared to other magnetic particle coatings known in the art with more limited coupling functionalities.
The invention is further illustrated by the following Examples.
EXAMPLES
Example 1 : Preparation of Superparamagnetic Magnetite Particles 200 grams (1.58 moles) of ferrous chloride (VWR Scientific) and 325 grams (2.0 moles) of ferric chloride were dissolved in 3 liters of water. 2000 grams of ammonium hydroxide (VWR Scientific) concentrate were added at a rate of 50 ml/minute under constant agitation, during which time the temperature of the solution was kept between 25 and 40°C. After the addition of the ammonium hydroxide was complete, the magnetic particle (Fe3O4) aqueous slurry was allowed to cool to room temperature.
Ex ample 2: Preparation of Amino - Hexyl - Titanium - Tri- Isopropoxide
0.1 moles of titanium- tri- isopropoxide (Tyzor TPT Dupont, Wilmington, DE) and 0.1 moles of 6-amino-1- hexanol were added to a 50 ml beaker and stirred at room temperature for 1 minute to form 0.1 mole of amino-hexyl- titanium- tri - isopropoxide. The reaction mixture was heated to 70°C for 10 minutes to evaporate the isopropyl alcohol formed during the reaction.
The material was cooled to room temperature and used as a monomer in making the tetravalent titanium organo- metallic coating in Example #3.
Example 2 : Preparation of Amine Functional Organo- titanate Coated Magnetic Particle According to the procedure s et out in Exampl e 1 , 4 moles FeCl3 and 2 moles of FeCl2 were dissolved in 4 L of distilled water and precipitated with 16 moles of ammonium hydroxide. The precipitate was washed 5 time s with water and 3 times with acetone. N,N-dimethyl formamlde (DMF) was added to the precipitate in the following ratio: 10 ml of DMF per gram of Fe3O4. The mixture was loaded into a Eiger Mill and mill e continuously for 10 minutes. The mixture was then transferred to a beaker and heated with stirring for 30 minutes at 100°C. The amine functional organo-titanate prepared in Example 2 was immediately added after preparation with constant stirring to the mixture in a ratio of 1 g dry Fe3O4 per 3 g of amine functional organo-titanate.
This mixture was then heated with stirring for 20 minutes at 65ºC and then passed through the Eiger Mill for two passes. The resulting material was washed five times with water, the coated particles were c o l l e c te d with an external magnetic field of 2000 gauss and the aqueous waste was decanted.
Example 4: Preparation of An Alternating Functional-Non Functional Organo-Titanate Monomer
The procedure described in Example 2 was fo l lowe d except that the organo-titanate was reacted with a comixture of amino-functional hexanol and hexanol to produce a monomer having reduced amine functionality. Hexanol and 6 -amino- 1 -hexanol in a molar ratio of 6:1 were mixed in a 50 ml beaker for one minute. Tyzor TPT was added to the alcohol mixture in the ratio of 1 mole of alcohol per mole of Tyz or TPT. The reaction mixture was s tirred for one minute , he ated to 70 ° C fo r 10 minutes to evaporate the isopropyl alcohol produced by the reaction and cooled to room temperature. The resulting compound was an organotitanate, 6 - amino -hexyl-titanium- tri-isopropoxide having alternating non- functional hexyl groups, that is, hexyl chains lacking the amino group. The weight ratios of 6 - amino - 1 -hexanol: Tyzor TPT:hexanol were 1:26:9.6. This compound was used as a monomer to make an organo - titanium coating as described in Example 5.
Example 5 : Preparation of Amine Functional Organotitanate Magnetic Particles
The procedure described in Example 3 was followed except that the amine-functional organo-titanate was the material prepared in Example 5. The mixture of magnetic particles and organo-titanate monomer was heated to 95°C for one hour with constant stirring and milled in an
Eiger Mill for 4 minutes. The mixture was washed nine times with water. Adipic acid was added in the ratio of 0.5 moles of adipic acid per mole of total particles. One mole of carbodiimide (CDI) was added, and the mixture was mixed for 30 minutes on a ball mill. 1,6 hexane- diamine was added in the ratio of 0.5 moles of 1,6 hexane-diamine per mole of total particles. One mole of CDI was added and the mixture was mixed for 30 minutes. The resulting material was washed five times with water, the particles were collected using an external magnetic field of 2000 gauss and the aqueous waste was decanted.
Example 6 : Preparation of Subdomain Magnetite Particles by Reaction of Particulate Ferrocene and Iron (II) Hydroxide A 100 g of a slurry containing 20% ferrocene (by weight) (dicyclopentadenyliron; Strem Chemical Co., Newburyport, MA) in water was prepared by mixing the ferrocene with the water. The slurry was added to a commercial ball mill. The mill was filled halfway with ¼ " stainless steel balls and the slurry was milled for a period of 2 hours.
A second ferrous hydroxide slurry (iron (II) hydroxide) was made according to the following procedure. An aqueous solution containing 20g of ferrous sulfate (VWR Scientific) was precipitated using 50g of ammonium hydroxide concentrate to form gelatinous ferrous hydroxide. The gel was filtered and the filtrate washed with 5 to 100g volumes of water. The washed gel was then made into a 10% aqueous slurry and milled as previously described for 5 hours.
The ferrocene and hydroxide slurries were mixed, and the mixture was milled for one day to form fine Fe3O4 particles. The particles were about 100 A in diameter and were responsive to a magnetic field. These particles can be coated as described in Examples 2-5 above.
Example 7 : Preparation of Subdomain Nickel-Ferrite Particles Subdomain nickel-ferrite particles were prepared according to the procedure set out in Example 6, except that a mixture of 50g a 20% nickelocene slurry (dicyclopentadenylnickel; Strem Chemical Co., Newburyport, MA) and 50g of a 20% ferrocene slurry were used in lieu of the 100g of the ferrocene slurry in Example 6. Magnetically responsive nickel-ferrite particles having a particle size of about 100 A were produced by this method.
Example 8 : Preparation Subdomain Cobat- Ferrite Particles Subdomain cobalt - ferrite particles were prepared according to the procedure set out in Example 6, except that a mixture of 50g of a 20% (by wt.) cobaltocene slurry (dicyclopentadenylcobalt; Strem Chemical Co., Newburyport, MA ) and 50g of the ferrocene slurry were used in lieu of 100g of the ferrocene slurry in Example 6. Magnetically responsive cobalt-ferrite particles having a particle size of about 100 A were produced by this method.
Example 9 : Preparation of Subdomain Metal Particles by Sodium Borohydride Reduction and Size Reduction by Milling 200 gm (1.58 moles) of ferrous chloride was dissolved in 1 liter of water. 500 gm of dry sodium borohydride were added to the solution to form a fine iron powder precipitate. The precipitate was washed with water and collected by filtration. The filtered powder was resuspended in water and re-filtered. The washing procedure was done 4 additional times. On the final suspension, the slurry was adjusted to a concentrate of 20% and milled as described in Example 6 for a period of 75 days to produce particles with a mean diameter of less than 50 A.
Equivalents
Those skilled in the art will recognize, or be able to ascertain, by no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following Claims.

Claims

1. A coated magnetically responsive particle comprising: a) a magnetic core particle comprising a magnetically- responsive metal, metal alloy or metal oxide; and b) an organo-metallic polymer coating covalently bonded to or adsorbed onto said particle, wherein the organo-metallic polymer coating is capable of binding at least one type of bioaffinity adsorbent.
2. A coated magnetically responsive particle of Claim 1, wherein the magnetic core particle comprises a metal, metal alloy or metal oxide selected from the group consisting of iron, magnetite, iron magnesium oxide, iron manganese oxide, iron cobalt oxide, iron nickel oxide, iron zinc oxide and iron copper oxide.
3. A coated magnetically responsive particle of Claim 2 wherein the magnetic core particle is magnetite.
4. A coated magnetically responsive particle of Claim 1 having a particle size of from about 0.003 to about 1.5 microns in diameter.
5. A coated magnetically responsive particle of Claim 1 wherein the organo-metallic polymer is formed from monomers which are coordinate complexes of organic ligands and a metal selected from the group consisting of: titanium, zirconium, hafnium, vanadium, tanatalum, niobium, tin and antimony.
6. A coated magnetically responsive particle of Claim 5 wherein the metal is titanium.
7. A coated magnetically responsive particle of Claim 1 wherein the organo-metallic polymer is an organo-titanium polymer selected from the group consisting of: titanium- tetra- isopropoxide, amino-hexyl-titanium-triisopropoxide, amino-propyl-titanium-triisopropoxide and carboxyl-hexyl-titanium triisopropoxide.
8. A coated magnetically responsive particle of Claim 7 wherein the organo-titanium polymer is amino-hexyl- titanium-tri-isopropoxide.
9 A coated magnetically responsive particle of Claim 1 which is superparamagnetic.
10. A coated magnetically responsive particle comprising: a) a magnetic core particle comprising a magnetically responsive metal, metal alloy or metal oxide; b) an organo- titanium polymer coating which is covalently bonded to or adsorbed onto the particle, said organo - titanium polymer having organic functional groups attached thereto; and c) a bioaffinity adsorbent covalently coupled to the organic function groups of the polymer coating.
11. A coated magnetically responsive particle of Claim 10, wherein the magnetic core particle is metal, metal alloy or metal oxide selected from the group consisting of: iron, magnetite, iron magnesium oxide, iron manganese oxide, iron cobalt oxide, iron nickel oxide, iron zinc oxide and iron copper oxide.
12. A coated magnetically responsive particle of Claim 11 wherein the magnetic core comprises magnetite.
13. A coated magnetically responsive particle of Claim 10 wherein the organo - titanium polymer coating is amino -hexyl - titanium- tri -isopropoxide.
14. A coated magnetically responsive particle of Claim 10 wherein the bioaffinity adsorbent is selected from the group consisting of: antibodies, antigens, enzymes and specific binding proteins.
15. A coated magnetically responsive particle of Claim 10 which is superparamagnetic.
16. A coated magnetically responsive particle of Claim 10, wherein the organic functional groups are selected from the group consisting of: amino, carboxyl, hydroxyl, sulfate, phosphate, cyanate and thiol groups.
17. A coated magnetically responsive particle of Claim 10 having a mean diameter of from about 0.003 to about 1.5 microns.
18. A magne t ically responsive particle comprising a superparamagnetic metal oxide core surrounded by an organo-titanium polymer to which bioaffinity adsorbents can be covalently coupled, the metal oxide core comprising a group of crystals of metal oxide, and the particle having a mean diameter of about 0.003 to about 1.5 microns.
19. A method of measuring analytes in a sample comprising the steps of: a. contacting a sample containing an unknown concentration of the analyte with a known amount of a labeled analyte in the presence of magnetic particles comprising: (i) a magnetic core particle comprising a magnetically responsive metal, met.al alloy or metal oxide; and (ii) an organo-metallic polymer coating covalently bonded to or adsorbed onto said particle, wherein said organo-metallic coating having a bioaffinity adsorbent covalently coupled thereto, said bioaffinity adsorbent is capable of binding to or interacting with both the unlabeled and the labeled analyte; b. maintaining the mixture obtained in step (a) under conditions sufficient for said binding or interaction to occur; c. magnetically separating the magnetic particles; and d. measuring the amount of label associated with the magnetic particles and determining the concentration of analyte in the sample.
20. A method of Claim 19 wherein the analyte is s e l e c te d from the group consisting of: antibodies, antigens, haptens, enzymes, apoenzymes, enzymatic substrates, enzymatic inhibitors, cofactors, nucleic acids, binding proteins, carrier proteins, compounds bound by binding proteins, compounds bound by carrier proteins, lectins, monosaccharides, polysaccharides, hormones, receptors, repressors and inducers.
21. A method of Claim 19 wherein the magnetic core particle comprises a metal, metal alloy or metal oxide selected from the group consisting of: iron, magnetite, iron magnesium oxide, iron manganese oxide, iron cobalt oxide, iron nickel oxide, iron zinc oxide and iron copper oxide.
22. A method of Claim 21 wherein the magnetic core particle has a particle size of from about 0.003 to about 1.5 microns in diameter.
23. A method of Claim 19 wherein the organo-metallic polymer coating is formed from monomers which are coordinate complexes of organic ligands and a metal selected from the group consisting of: titanium, zirconium, hafnium, vanadium, tantalum, niobium, tin and antimony.
24. A method of Claim 23 wherein the organo-metallic polymer is an organo- titanium polymer selected from the group consisting of: titanium-tetra- isopropoxide, amino-hexyl-titanium triisopropoxide, amino-propyl-titanium isopropoxide and carboxyl- hexyl-titanium triisopropoxide.
25. A method of Claim 19 wherein the magnetically responsive particle is superparamagnetic.
26. A method of Claim 19 wherein the bioaffinity adsorbent is selected from the group consisting of: antibodies, antigens, haptens, enzymes, apoenzymes, enzymatic substrates, enzymatic inhibitors, cofactors, nucleic acids, binding proteins, carrier proteins, compounds bound by binding proteins, compounds bound by carrier proteins, lectins, monosaccharides, polysaccharides, hormones, receptors, repressers and inducers.
27. A method of Claim 19 wherein the labeled analyte is marked with a label selected from the group consisting of: radioisotopes, fluorescent compounds, enzymes and chemiluminescent compounds.
EP19910902915 1989-12-22 1990-12-18 Organo-metallic coated particles for use in separations Ceased EP0506880A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45507189A 1989-12-22 1989-12-22
US455071 1989-12-22
US56616990A 1990-08-10 1990-08-10
US566169 1990-08-10

Publications (1)

Publication Number Publication Date
EP0506880A1 true EP0506880A1 (en) 1992-10-07

Family

ID=27037705

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910902915 Ceased EP0506880A1 (en) 1989-12-22 1990-12-18 Organo-metallic coated particles for use in separations

Country Status (3)

Country Link
EP (1) EP0506880A1 (en)
JP (1) JPH05502944A (en)
WO (1) WO1991009678A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441746A (en) * 1989-12-22 1995-08-15 Molecular Bioquest, Inc. Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
US5389377A (en) * 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5935866A (en) * 1989-12-22 1999-08-10 Binax Nh, Inc. Preparation of sub 100 A magnetic particles and magnetic molecular switches
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
JPH08500700A (en) * 1992-06-08 1996-01-23 バイオクエスト インコーポレイテッド Manufacture of controlled particle size inorganic particles for use as inorganic liposomes for separations, magnetic molecular switches, and medical applications
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
JP3662347B2 (en) * 1996-06-10 2005-06-22 日鉄鉱業株式会社 Medical powder
AUPP004497A0 (en) * 1997-10-28 1997-11-20 University Of Melbourne, The Stabilized particles
DE19821968A1 (en) * 1998-05-18 1999-11-25 Studiengesellschaft Kohle Mbh Production of transition metal colloid for use e.g. as coating, catalyst, fuel cell component and in ink jet printing, laser etching, information storage and cell labeling and cell separation
EP1115888B1 (en) 1998-09-24 2008-03-12 Indiana University Research and Technology Corporation Water-soluble luminescent quantum dots and bioconjugates thereof
EP1522318A3 (en) * 1999-04-09 2005-07-06 Advanced Magnetics Incorporated Heat stable coated colloidal iron oxides
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
DK1169062T3 (en) 1999-04-09 2010-01-25 Amag Pharmaceuticals Inc Heat stable coated colloidal iron oxides
CA2514010A1 (en) 2004-08-03 2006-02-03 Axis-Shield Diagnostics Limited Assay
US8119162B2 (en) 2005-11-10 2012-02-21 Colgate-Palmolive Company Particles that disrupt or impede bacterial adhesion, related compositions and methods
JP5221897B2 (en) * 2007-05-22 2013-06-26 栄研化学株式会社 Nucleic acid recovery reagent, nucleic acid amplification reagent kit using the same, nucleic acid recovery method and nucleic acid amplification method using the same
CN102947340A (en) * 2010-05-10 2013-02-27 拜欧雷耶私人有限公司 Binding systems
CN103217529B (en) * 2013-03-17 2015-07-01 南昌大学 Gamma-Fe2O3 nanoparticle indirect enrichment immunomagnetic separation based method for rapid detection of food-borne pathogenic bacteria
CN103185796B (en) * 2013-03-17 2015-05-20 南昌大学 Food-borne pathogenic bacteria quick detection method based on Gamma-Fe2O3@Au nano particle indirect enrichment and immunomagnetic separation
EP3033360B1 (en) 2013-08-13 2019-11-27 Anteo Technologies Pty Ltd. Conjugating molecules to particles
CN111841881A (en) * 2020-07-29 2020-10-30 攀钢集团矿业有限公司 Method for recovering titanomagnetite in beneficiation process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8104307A (en) * 1981-09-18 1983-04-18 Oce Nederland Bv COLORED TONER POWDER, A METHOD FOR ITS PREPARATION AND A METHOD FOR DEVELOPING IMAGES WITH THIS POWDER.
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
DE3582649D1 (en) * 1984-11-01 1991-05-29 Technicon Instr MAGNETICALLY SENSITIVE REAGENT AND METHOD FOR THE PRODUCTION THEREOF.
US4814098A (en) * 1986-09-06 1989-03-21 Bellex Corporation Magnetic material-physiologically active substance conjugate
FR2624873B1 (en) * 1987-12-18 1992-01-10 Rhone Poulenc Chimie MAGNETISABLE COMPOSITE PARTICLES BASED ON CROSSLINKED ORGANOPOLYSILOXANE, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN BIOLOGY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9109678A1 *

Also Published As

Publication number Publication date
JPH05502944A (en) 1993-05-20
WO1991009678A1 (en) 1991-07-11

Similar Documents

Publication Publication Date Title
US4695392A (en) Magnetic particles for use in separations
US4695393A (en) Magnetic particles for use in separations
US4554088A (en) Magnetic particles for use in separations
US4698302A (en) Enzymatic reactions using magnetic particles
US4628037A (en) Binding assays employing magnetic particles
US4672040A (en) Magnetic particles for use in separations
EP0506880A1 (en) Organo-metallic coated particles for use in separations
Halling et al. Magnetic supports for immobilized enzymes and bioaffinity adsorbents
US7169618B2 (en) Magnetic particles and methods of producing coated magnetic particles
US5169754A (en) Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same
US6773812B2 (en) Magnetically-responsive microspheres
WO1990015666A1 (en) Coated magnetic particles for use in separations
KR19990035924A (en) Magnetic polymer particles based on polyvinyl alcohol, methods of making and uses thereof
JPH03504303A (en) encapsulated superparamagnetic particles
JPH01503808A (en) Affinity separation using immobilized flocculants
JPS62226817A (en) Coated chromium dioxide particle
WO1993026019A1 (en) Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
US5935866A (en) Preparation of sub 100 A magnetic particles and magnetic molecular switches
GB2221466A (en) Biologically reactive particles with biological, therapeutic and chromatographic applications
Šafarík et al. Overview of magnetic separations used in biochemical and biotechnological applications
EP0543988B1 (en) Process for producing magnetically responsive polymer particles and application thereof
Koneracká et al. Immobilization of enzymes on magnetic particles
Zulquarnain Scale-up of affinity separation based on magnetic support particles
CA1266769A (en) Magnetic particles for use in separations
CA2082186A1 (en) Production of high binding capacity magnetizable particles of controlled size used in immunoassay systems

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT DE DK FR GB IT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MOLECULAR BIOQUEST, INC.

17Q First examination report despatched

Effective date: 19950109

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19960729